Integrated Safety Profile of a New Approved, Fully-liquid DTaP5-HB-IPV-Hib Vaccine

Background:DTaP5-HB-IPV-Hib is a fully-liquid, hexavalent vaccine containing a 5-antigen pertussis component; approved since 2016 in Europe (Vaxelis™) for primary and booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases